167 related articles for article (PubMed ID: 34123867)
1. Gut Microbiota Aberration in Patients of Systemic Sclerosis and Bleomycin-Induced Mice Model.
Tang J; Zhou X; Wu X; Lin S; Ming B; Zhong J; Wang B; Dong L
Front Cell Infect Microbiol; 2021; 11():647201. PubMed ID: 34123867
[TBL] [Abstract][Full Text] [Related]
2. Gut microbiota analysis in systemic sclerosis according to disease characteristics and nutritional status.
Natalello G; Bosello SL; Paroni Sterbini F; Posteraro B; De Lorenzis E; Canestrari GB; Gigante L; Verardi L; Ferraccioli G; Sanguinetti M; Gremese E
Clin Exp Rheumatol; 2020; 38 Suppl 125(3):73-84. PubMed ID: 32865168
[TBL] [Abstract][Full Text] [Related]
3. Gut microbiota profile in systemic sclerosis patients with and without clinical evidence of gastrointestinal involvement.
Patrone V; Puglisi E; Cardinali M; Schnitzler TS; Svegliati S; Festa A; Gabrielli A; Morelli L
Sci Rep; 2017 Nov; 7(1):14874. PubMed ID: 29093509
[TBL] [Abstract][Full Text] [Related]
4. The Microbiome in Systemic Sclerosis: Pathophysiology and Therapeutic Potential.
Kim S; Park HJ; Lee SI
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555792
[TBL] [Abstract][Full Text] [Related]
5. Intestinal microbiome in scleroderma: recent progress.
Volkmann ER
Curr Opin Rheumatol; 2017 Nov; 29(6):553-560. PubMed ID: 28719392
[TBL] [Abstract][Full Text] [Related]
6. Elevated frequencies of CD4(+) IL-21(+) T, CD4(+) IL-21R(+) T and IL-21(+) Th17 cells, and increased levels of IL-21 in bleomycin-induced mice may be associated with dermal and pulmonary inflammation and fibrosis.
Lei L; He ZY; Zhao C; Sun XJ; Zhong XN
Int J Rheum Dis; 2016 Apr; 19(4):392-404. PubMed ID: 25545680
[TBL] [Abstract][Full Text] [Related]
7. Congruent microbiome signatures in fibrosis-prone autoimmune diseases: IgG4-related disease and systemic sclerosis.
Plichta DR; Somani J; Pichaud M; Wallace ZS; Fernandes AD; Perugino CA; Lähdesmäki H; Stone JH; Vlamakis H; Chung DC; Khanna D; Pillai S; Xavier RJ
Genome Med; 2021 Feb; 13(1):35. PubMed ID: 33648559
[TBL] [Abstract][Full Text] [Related]
8. Sirt1 ameliorates systemic sclerosis by targeting the mTOR pathway.
Zhu X; Chu H; Jiang S; Liu Q; Liu L; Xue Y; Zheng S; Wan W; Qiu J; Wang J; Zou H
J Dermatol Sci; 2017 Aug; 87(2):149-158. PubMed ID: 28532580
[TBL] [Abstract][Full Text] [Related]
9. Gut microbiota in experimental murine model of Graves' orbitopathy established in different environments may modulate clinical presentation of disease.
Masetti G; Moshkelgosha S; Köhling HL; Covelli D; Banga JP; Berchner-Pfannschmidt U; Horstmann M; Diaz-Cano S; Goertz GE; Plummer S; Eckstein A; Ludgate M; Biscarini F; Marchesi JR;
Microbiome; 2018 May; 6(1):97. PubMed ID: 29801507
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of the dynamic changes in gut microbiota in patients with extremely severe burns by 16S ribosomal RNA high-throughput sequencing technology].
Pan YY; Fan YF; Li JL; Cui SY; Huang N; Jin GY; Chen C; Zhang C
Zhonghua Shao Shang Za Zhi; 2020 Dec; 36(12):1159-1166. PubMed ID: 33379852
[No Abstract] [Full Text] [Related]
11. Butyrate Improves Skin/Lung Fibrosis and Intestinal Dysbiosis in Bleomycin-Induced Mouse Models.
Park HJ; Jeong OY; Chun SH; Cheon YH; Kim M; Kim S; Lee SI
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803282
[TBL] [Abstract][Full Text] [Related]
12. Update on the Gastrointestinal Microbiome in Systemic Sclerosis.
Bellocchi C; Volkmann ER
Curr Rheumatol Rep; 2018 Jun; 20(8):49. PubMed ID: 29943234
[TBL] [Abstract][Full Text] [Related]
13. Th17 cells and IL-17 promote the skin and lung inflammation and fibrosis process in a bleomycin-induced murine model of systemic sclerosis.
Lei L; Zhao C; Qin F; He ZY; Wang X; Zhong XN
Clin Exp Rheumatol; 2016; 34 Suppl 100(5):14-22. PubMed ID: 26750756
[TBL] [Abstract][Full Text] [Related]
14. Probiotic alleviate fluoride-induced memory impairment by reconstructing gut microbiota in mice.
Xin J; Wang H; Sun N; Bughio S; Zeng D; Li L; Wang Y; Khalique A; Zeng Y; Pan K; Jing B; Ma H; Bai Y; Ni X
Ecotoxicol Environ Saf; 2021 Jun; 215():112108. PubMed ID: 33799132
[TBL] [Abstract][Full Text] [Related]
15. The microbiome and systemic sclerosis: A review of current evidence.
Tan TC; Noviani M; Leung YY; Low AHL
Best Pract Res Clin Rheumatol; 2021 Sep; 35(3):101687. PubMed ID: 33849778
[TBL] [Abstract][Full Text] [Related]
16. Induction of autoimmunity in a bleomycin-induced murine model of experimental systemic sclerosis: an important role for CD4+ T cells.
Ishikawa H; Takeda K; Okamoto A; Matsuo S; Isobe K
J Invest Dermatol; 2009 Jul; 129(7):1688-95. PubMed ID: 19158840
[TBL] [Abstract][Full Text] [Related]
17. Gut microbiota modulates bleomycin-induced acute lung injury response in mice.
Yoon YM; Hrusch CL; Fei N; Barrón GM; Mills KAM; Hollinger MK; Velez TE; Leone VA; Chang EB; Sperling AI
Respir Res; 2022 Dec; 23(1):337. PubMed ID: 36496380
[TBL] [Abstract][Full Text] [Related]
18. Mouse model of experimental dermal fibrosis: the bleomycin-induced dermal fibrosis.
Avouac J
Methods Mol Biol; 2014; 1142():91-8. PubMed ID: 24706279
[TBL] [Abstract][Full Text] [Related]
19. Interferon regulatory factor 7 (IRF7) represents a link between inflammation and fibrosis in the pathogenesis of systemic sclerosis.
Wu M; Skaug B; Bi X; Mills T; Salazar G; Zhou X; Reveille J; Agarwal SK; Blackburn MR; Mayes MD; Assassi S
Ann Rheum Dis; 2019 Nov; 78(11):1583-1591. PubMed ID: 31439591
[TBL] [Abstract][Full Text] [Related]
20. Critical Appraisal of the Utility and Limitations of Animal Models of Scleroderma.
Tsujino K; Sheppard D
Curr Rheumatol Rep; 2016 Jan; 18(1):4. PubMed ID: 26711695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
